Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection.

ABSTRACT:

Background

Although symptom and viral rebound have been reported after nirmatrelvir-ritonavir treatment, the trajectories of symptoms and viral load during the natural course of COVID-19 have not been well described.

Objective

To characterize symptom and viral rebound in untreated outpatients with mild to moderate COVID-19.

Design

Retrospective analysis of participants in a randomized, placebo-controlled trial. (ClinicalTrials.gov: NCT04518410).

Setting

Multicenter trial.

Patients

563 participants receiving placebo in the ACTIV-2/A5401 (Adaptive Platform Treatment Trial for Outpatients With COVID-19) platform trial.

Measurements

Participants recorded the severity of 13 symptoms daily between days 0 and 28. Nasal swabs were collected for SARS-CoV-2

SUBMITTER: Deo R 

PROVIDER: S-EPMC10052317 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature